Introduction {#s1}
============

Prostate cancer (PCa) is the second leading cause of male cancer deaths in the Western countries and an increasing problem in those adopting Western lifestyle and diet. Advances in screening and diagnosis have allowed the detection of tumors at earlier stages, when curative therapy is still feasible. For late stage disseminated disease however, current therapies are merely palliative and no curative treatment exists. Since the growth of prostate tumors is originally androgen-dependent, metastatic cancers are generally treated with androgen ablation therapy, with or without antiandrogen supplementation [@pone.0013500-Crawford1], [@pone.0013500-Eisenberger1]. The vast majority of these patients show a significant clinical regression, but the cancer eventually recurs within 12--18 months. These recurrent tumors have escaped androgen suppression and became resistant to hormonal therapy, referred to as hormone-refractory or castration-resistant PCa. To survive and resume growth in an androgen-deprived environment PCa cells must either adapt the androgen receptor (AR) pathway to the androgen-depleted conditions or invoke alternative survival and growth pathways [@pone.0013500-Jenster1]. Much experimental evidence exists to support both mechanisms, which are not necessarily mutually exclusive. AR expression was shown to be maintained in the majority of patients that underwent hormonal therapy and showed recurrence of disease, suggesting a role of the AR also in late stage disease [@pone.0013500-vanderKwast1], [@pone.0013500-RuizevelddeWinter1]. Moreover, the AR gene is amplified and/or overexpressed in about 30% of the hormone-therapy refractory tumors, and it has been proposed this could sensitize the receptor for the residual androgen concentrations and antiandrogens present under hormonal therapies [@pone.0013500-Brown1], [@pone.0013500-Koivisto1], [@pone.0013500-Linja1]. Furthermore, several AR mutations, resulting in increased activity or broadened ligand-specificity to alternative steroids and antiandrogens, have been associated with disease progression [@pone.0013500-Culig1], [@pone.0013500-Taplin1]. Other modifications of the AR pathway that may induce hormone-refractory growth include intratumoral steroidogenesis, ligand-independent activation by cross-talk with other signaling pathways, alterations in the balance of AR co-regulators or expression of constitutively active truncated AR isoforms [@pone.0013500-Jenster1], [@pone.0013500-Grossmann1], [@pone.0013500-Devlin1]. Interestingly, recent work from others and us has revealed that the AR pathway may be selectively attenuated in advanced/metastatic disease [@pone.0013500-Hendriksen1], [@pone.0013500-Tomlins1], [@pone.0013500-Mendiratta1]. Since the AR pathway is also involved in processes of cellular differentiation and prostate maturation, it is tempting to suggest that PCa cells may eventually gain growth advantage by inhibiting the AR induced differentiation. Prompted by these results, we focused the present study on alternative survival and growth pathways, which are independent of AR activation. To effectively bypass the AR pathway, cancer epithelial cells must be able to survive the apoptotic signals triggered by hormonal therapies and invoke alternative growth pathways. Autocrine production of growth factors or its receptors, activation of oncogenes and inhibition of tumor-suppressor genes are all possible mechanisms for bypassing the AR pathway. Consistent with this hypothesis, paracrine growth factors that are normally secreted by prostate stroma cells, such as epidermal growth factor (EGF), insulin-like growth factor 1 (IGF1), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF) or interleukin 6 (IL6), are found to be overexpression in hormone-refractory cancer in association with a switch to autocrine production by cancer epithelial cells [@pone.0013500-Berry1]. In addition to being potential mitogens, mounting evidence indicates that these growth hormones are also able to cross-talk with the AR signaling pathway, leading to expression of AR target genes in the absence of androgens [@pone.0013500-Zhu1]. Therefore, it still has to be established whether the autocrine production of these growth factors represents an adaptation or a true bypass of the AR signaling pathway. Alterations in the anti-apoptotic *BCL2* oncogene and in the pro-apoptotic *P53* and *PTEN* tumor-suppressor genes have also been found in prostate cancer [@pone.0013500-Lee1], [@pone.0013500-Gurumurthy1]. However, these events mostly occur before late stage progression, making them less likely candidates for the switch to hormone-refractory growth in late stage disease. Nevertheless, by inhibiting PCa cell death and shifting the balance towards cellular proliferation, genes involved in the regulation of apoptosis may also play a role in hormone-refractory growth.

To explore the mechanism(s) by which androgen-dependent PCa cells become resistant to hormonal therapy, we used microarray technology to interrogate the differences in gene expression between androgen-responsive and therapy-resistant cell lines. As model system we used the androgen-responsive PC346C cell line and its therapy-resistant sublines PC346DCC, PC346Flu1 and PC346Flu2. These sublines were derived from the parental PC346C by long-term androgen ablation (PC346DCC), supplemented with the antiandrogen hydroxyflutamide (PC346Flu1 and PC346Flu2) [@pone.0013500-Marques1], [@pone.0013500-Marques2]. Previous studies revealed distinct AR modifications in all three therapy-resistant sublines, which corresponded to diverse mechanism of hormone-refractory growth. Whereas PC346DCC, expressing very low levels of AR and PSA, showed evidence of bypassing of the AR pathway, PC346Flu1 exhibited 4-fold AR up-regulation and PC346Flu2 was shown to carry the T877A AR mutation. Both PC346Flu1 and PC346Flu2 sublines replicate the progression to hormone-therapy refractory disease through adaptations of the AR pathway. Therefore, we focused on the PC346DCC subline to select for genes particularly involved in the bypass of the AR pathway. In addition to providing novel insights into the mechanisms of PCa progression, the genes identified here may prove useful as prognostic markers and potential targets for novel therapeutical approaches.

Methods {#s2}
=======

Reagents and cell lines {#s2a}
-----------------------

The PC346C cell line was derived from the prostate tumor of a patient with non-progressive prostate adenocarcinoma (T4N0M0) [@pone.0013500-Marques1], [@pone.0013500-Marques2]. The PC346DCC, PC346Flu1 and PC346Flu2 sublines were derived from PC346C upon long-term culture in charcoal-stripped medium, without or with antiandrogen hydroxyflutamide supplementation, respectively. The development and characterization of these cell lines has been published previously [@pone.0013500-Marques1], [@pone.0013500-Marques2]. The basic culture medium used in the maintenance of PC346 cell lines consisted of DMEM-F12 medium (Cambrex BioWhitaker, Belgium) supplemented with 2% fetal calf serum (FCS; PAN Biotech GmbH, Aidenbach, Germany), 1% insulin-transferrin-selenium (Gibco BRL), 0.01% bovine serum albumin (Boehringer Mannheim, Germany), 10 ng/ml epidermal growth factor (Sigma-Aldrich), penicillin/streptomycin antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin; BioWhitaker, Belgium); plus the following additions: 100 ng/ml fibronectin (Harbor Bio-Products, Tebu-bio, The Netherlands), 20 mg/ml fetuine (ICN Biomedicals, The Netherlands), 50 ng/ml choleratoxin, 0.1 mM phosphoethanolamine, 0.6 ng/ml triiodothyronine and 500ng/ml dexametason (all from Sigma). PC346C cells were maintained in culture in the complete medium described above, supplemented with 0.1 nM 17-methyltrienolone (R1881; NEN, Boston MA, USA). PC346DCC selection medium was supplemented as described above, but depleted from androgens by using dextran-coated charcoal (DCC) treated FCS. PC346Flu1 and PC346Flu2 culture medium was also androgen depleted by using 2% DCC-FCS, and supplemented with 1 µM of hydroxyflutamide (OH-flutamide, Schering-Plough Research Institute, New Jersey, USA).

Cells were grown in T25 Primaria™ tissue culture flasks (BD Biosciences Benelux N.V, The Netherlands) at 37°C under 5% CO~2~ humidified atmosphere.

Expression microarray analysis {#s2b}
------------------------------

Cells were seeded in their respective selection medium to reach ∼50% confluency and allowed to grow for 2 days. Then, cells were rinsed twice with PBS and stored at −20°C until RNA isolation. Total RNA was isolated with RNAzol B reagent (Campro Scientific, Veenendaal, The Netherlands) and further purified through RNeasy columns (Qiagen) with on-column DNA digestion, according to the manufacturer\'s protocol. RNA quality was checked on 1% agarose gel.

Cy3- or Cy5-labelled RNA probes were produced by incorporating amino-allyl UTP during RNA amplification, followed by coupling to N-hydroxysuccinimide modified dye. Briefly, 3 µg RNA was used for a T7-based linear mRNA amplification protocol, described previously [@pone.0013500-Baugh1]. Amino-allyl UTP, plus equal amount of unmodified rUTP, was incorporated into aRNA with T7 Megascript Kit (all from Ambion), according to manufacturer\'s protocol. Amplified RNA was purified and concentrated using Microcon-YM 30 columns (Amicon®) to rinse three times with 300 µl RNAse-free water. Finally, 2 µg aminoallyl-modified RNA, in a maximum of 3.33 µl of RNAse-free water, was incubated with 1.66 µl sodium bicarbonate buffer (0.3 M, pH 9) and 5 µl Cy3- or Cy5- dye (CyScribe Post-Labeling Kit, Amersham, NJ, USA), for 1 h in the dark at room temperature. Reaction was stopped with 5 µl 4 M hydroxylamine HCl (Sigma), contra-labelled probes were combined and purified/concentrated using Microcon-YM 30. Probe was collected in 5--15 µl final volume and resuspended in 80 µl Ambion hybridization buffer number 1.

For the microarray we used double-dye oligoarrays representing about 15,000 human genes, on which labelled RNA from the each therapy-resistant subline was cohybridized with contra-labelled PC346C. Four microarrays were performed per condition, using two distinct cell passages in dye-swap. This was done to account for the biological variability and to exclude dye-preferential binding to oligonucleotides on the microarray. The oligoarrays used in this study were produced at the Erasmus Center for Biomics. Briefly, a human 18,584 oligonucleotides library (Compugen, Sigma-Genosys) was spotted on aminosilane slides using a Virtek Chipwriter Professional arrayer (Virtek Vision International, Waterloo, Canada). Control spots included landmarks, spotting buffer, alien oligonucleotides (SpotReport Alien Oligo Array, La Jolla, Stratagene), poly d\[A\]40--60, salmon sperm DNA, and human COT-1 DNA. Before the hybridization, microarray slides were prehybridized in 5x SSC, 0.05% SDS, 4% BSA solution for 30 min at 45°C, washed twice with RNAse-free water for 2 min, rinsed with isopropanol and spin-dried for 3 min at 1500 g. Microarray hybridizations were performed overnight at 45°C, with continuous agitation, in a HS4800 Hybridization Station (Tecan Benelux BV). Finally, the arrays were washed automatically in the Hybridization Station using: 2x SSC/0.05% SDS (at 45°C), 1x SSC and 0.2x SSC (at room temperature), and dried under a stream of N2, before scanning.

Data extraction and analysis {#s2c}
----------------------------

Arrays were scanned in a ScanArray Express HT scanner (Perkin Elmer, Nederland BV) and spot intensities were quantified using Imagene software (Bio Discovery Inc, El Sequndo, CA, USA). To balance Cy3 and Cy5 spot intensities, Loewess normalization per subarray was performed using limma-package (<http://bioinf.wehi.edu.au/limma/>) from Bioconductor (<http://www.bioconductor.org>) [@pone.0013500-Smyth1], [@pone.0013500-Smyth2]. To scale between arrays, the global median intensity per array was set at 1000. Dye intensities below 200 were then thresholded at 200, to minimize noise and make fold-change on the low-intensity range more robust against outliers. Spots with intensities below the threshold (200) for both Cy3 and Cy5 channels in more than 2 of the 4 arrays performed per subline were excluded from the analysis. Sample to reference ratios were then calculated and 2log transformed. Spots that showed opposite effects for the dye-swap/biological replicates were excluded from further analysis; effects were called opposite if the mean 2log ratio for the per subline were ≥0.5 for one dye and below ≤−0.5 for the dye-swap. Following normalization and all the above-mentioned quality controls, the 2log intensity ratios were averaged for the replicates of each subline. This data was stored in SRS7 (Sequence Retrieval System version 7, Lion Bioscience AG, Heidenberg, Germany), which was also used for the comparisons with other previously published/publicly available databases [@pone.0013500-Veldhoven1]. The microarray data was deposited in the Gene Expression Omnibus repository (<http://www.ncbi.nlm.nih.gov/geo/> under the GEO accession number GSE21596). Hierarchical clustering and data visualization was performed using Cluster and TreeView programs (Eisen Labs: <http://rama.lbl.gov>). Significance Analysis of Microarrays (SAM; <http://www-stat.stanford.edu/~tibs/SAM>) was used to determine which genes were statistically different between stimulated samples and non-stimulated references. Gene ontology clustering was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID: <http://david.abcc.ncifcrf.gov>) [@pone.0013500-Dennis1], [@pone.0013500-Huangda1]. The pathway and functional analyses were generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com)).

cDNA synthesis and RT- PCR analysis {#s2d}
-----------------------------------

Normal and tumor specimens from patients used for quantitative real-time RT-PCR analysis were obtained from the frozen tissue bank of the Erasmus Medical Center (Rotterdam, the Netherlands). The specimens were collected between 1984 and 2001. The experimental protocols were approved by the Erasmus MC Medical Ethics Committee according to the Medical Research Involving Human Subjects Act. Additional information about these specimens was provided previously.[@pone.0013500-vanderHeulNieuwenhuijsen1] Total RNA was isolated as described above and cDNA was synthesized using MMLV-reverse transcriptase kit and Oligo(dT)~12--18~ primer (Invitrogen), according to manufacturer\'s protocol. cDNA samples were stored at −20°C. TaqMan real-time PCR analysis was performed in an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA), using AmpliTaq Gold DNA polymerase (Applied Biosystems), according to manufacturer\'s specifications. Validated primers and probes from TaqMan Gene Expression Assays (Applied Biosystems) were used for quantification of VAV3 (Hs00916821_m1), TWIST1 (Hs00361186_m1), DKK3 (Hs00951307_m1) and GAPDH (Hs99999905_m1), according to the PCR settings provided by Applied Biosystems. PBGD was quantified using 0.33 µM of primers forward: CATGTCTGGTAACGGCAATG and reverse: GTACGAGGCTTTCAATGTTG primers, in Power SybrGreen PCR Master Mix (Applied Biosystems), according to thermocycling protocol recommended by the manufacturer. Transcript quantities for each sample were normalized against the average of two endogenous references and relative to a calibrator. The two housekeeping genes used as endogenous references were *PBGD* and *GAPDH*; a mixture of cDNAs from prostate carcinoma xenografts was used as the calibrator. Graphs and statistics were performed with GraphPad Prism (version 3.0). P-values \<0.05 were considered significant.

Results {#s3}
=======

Differential gene expression profile between the androgen-responsive PC346C and its therapy-resistant sublines {#s3a}
--------------------------------------------------------------------------------------------------------------

Expression array analysis was performed to explore whether the AR pathway is still active in the hormone-therapy refractory cells under androgen-deprived conditions and identify putative alternative growth/survival pathways. Each of the therapy-resistant sublines were cultured in their respective selection medium (steroid-stripped medium for PC346DCC, supplemented with 1 µM OH-flutamide for PC346Flu1 and Flu2) and hybridized on the microarrays, together with the parental androgen-responsive PC346C (cultured in complete medium supplemented with 0.1 nM R1881). To account for the biological variability and dye-preferential binding to oligonucleotides on the microarray, four arrays were performed per condition, using two independent cell passages in dye-swap. Variation in expression pattern was analysed per therapy-resistant subline, and spots were considered to be differentially expressed if the absolute 2log ratio ≥ 0.5 (ratio ≥ 1.42 or ≤0.71) for at least three of the 4 arrays and for the average of all 4 arrays. According to these criteria, there were a total of 487 differentially regulated transcripts in the therapy-resistant sublines compared to androgen-sensitive PC346C, most of which were overlapping all three refractory sublines ([Fig. 1](#pone-0013500-g001){ref-type="fig"}). With 276 differentially regulated transcripts, PC346DCC showed the strongest divergence from the parental line, whereas PC346Flu2 revealed the least alterations (127 transcripts). Significance Analysis of Microarrays (SAM) was used to determine statistical significance of the selected genes and, at a 5% false discovery rate, 392 of the 487 (80%) selected reached statistical significance. The top 100 differentially expressed genes between the therapy-resistant and the androgen-responsive cell lines, respective expression ratios and statistical analysis are presented in [Tables 1](#pone-0013500-t001){ref-type="table"} and [2](#pone-0013500-t002){ref-type="table"}. A comprehensive list of all the regulated genes per subline is provided in [Tables S1](#pone.0013500.s001){ref-type="supplementary-material"} to [S3](#pone.0013500.s003){ref-type="supplementary-material"}. Interestingly, a considerable proportion (64/487) of the differentially regulated genes clustered at distinct genomic locations on chromosomes 4, 5, 6, 8, 11 and 18 (p-value\<0.05; [Table 3](#pone-0013500-t003){ref-type="table"}).

![Differentially-expressed genes in PC346DCC, PC346Flu1 and PC346Flu2 sublines compared to the androgen-responsive PC346C.\
PC346C was cultured in complete medium with 0.1 nM R1881, whereas the hormone-refractory sublines were culture in dextran-coated charcoal stripped medium (PC346DCC), supplemented with 1 µM of the antiandrogen hydroxyflutamide (PC346Flu1 and PC346Flu2). A) Heat-map representation: red and green colors represent up-regulation and down-regulation, respectively, whereas black indicates no difference between sublines and parental PC234C cells. Grey squares indicate missing data, either due to low expression levels, poor data quality or absence of probes for the respective transcript in the array platform used for the study. B) Venn-diagram of the number of regulated genes in the different sublines.](pone.0013500.g001){#pone-0013500-g001}
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###### Top 50 genes overexpressed in the therapy-resistant cell lines, expression ratios and SAM q-values.

![](pone.0013500.t001){#pone-0013500-t001-1}

  GenBank        Cytoband                    HUGO symbol                                             HUGO Gene Name                              PC346DCC   PC346Flu1   PC346Flu2                 
  ----------- -------------- ------------------------------------------- ---------------------------------------------------------------------- ---------- ----------- ----------- ------- ------ -------
  NM_004982      12p11.23                       KCNJ8                          potassium inwardly-rectifying channel subfamily J member 8          2.7        0.000        1.2      0.000   1.9    0.000
  NM_000790        7p11                          DDC                             dopa decarboxylase aromatic L-amino acid decarboxylase            1.9        0.005        0.1      0.253   2.4    0.218
  NM_013452        Xp22                          VCX                                            variable charge X-linked                           2.3        0.000        1.6      0.015   1.7    0.049
  NM_014269        4q34                        ADAM29                                       ADAM metallopeptidase domain 29                        1.5        0.000        1.4      0.011   2.2    0.000
  NM_004750       19p12                         CRLF1                                       cytokine receptor-like factor 1                        2.1        0.000                               
  NM_006113       1p13.3                        VAV3                                    vav 3 guanine nucleotide exchange factor                   2.0        0.000        0.2      0.031   0.4    0.218
  NM_003226      21q22.3                        TFF3                                          trefoil factor 3 intestinal                          1.9        0.000       −0.5      0.211   1.5    0.049
  NM_001072        2q37                        UGT1A1                             UDP glucuronosyltransferase 1 family polypeptide A1              0.2        0.380        1.7      0.015   −0.1   0.714
  NM_006332      19p13.1                        IFI30                                    interferon gamma-inducible protein 30                     1.7        0.000        1.1      0.025   0.7    0.218
  NM_012463      12q24.31                     ATP6V0A2                               ATPase H transporting lysosomal V0 subunit a2                 0.8        0.028        1.2      0.051   1.7    0.000
  AB037810        1q42.2                       SIPA1L2                              signal-induced proliferation-associated 1 like 2               0.9        0.046        1.5      0.000   1.7    0.049
  NM_001823       14q32                          CKB                                             creatine kinase brain                             1.7        0.000        1.5      0.015   1.6    0.000
  NM_016084      17p11.2                        RASD1                                         RAS dexamethasone-induced 1                          1.6        0.000        1.2      0.000   0.5    0.218
  NM_005794      14q11.2                        DHRS2                                 dehydrogenase/reductase SDR family member 2                  1.4        0.003        1.5      0.071   1.2    0.051
  NM_013253      11p15.2                        DKK3                                       dickkopf homolog 3 Xenopus laevis                       −0.6       0.005        1.4      0.000   0.7    0.218
  AK026892       22q13.31                       CERK                                                ceramide kinase                                1.4        0.000        0.0      0.321   0.5    0.218
  NM_006721       10q22                          ADK                                                adenosine kinase                               1.4        0.000        0.1      0.422   0.7    0.194
  NM_005804      19p13.12                       DDX39                                   DEAD Asp-Glu-Ala-Asp box polypeptide 39                    1.4        0.000        0.3      0.253   0.8    0.194
  U58096          Yp11.2                        TSPY1                                      testis specific protein Y-linked 1                      1.0        0.037        1.4      0.000         
  S67154           3q28                        EIF4A2                            eukaryotic translation initiation factor 4A isoform 2             0.1        0.589        1.3      0.021   −0.5   0.101
  AL049949       10q22.3                      C10orf56                                    chromosome 10 open reading frame 56                      1.3        0.000        0.5      0.048   0.4    0.218
  NM_016639      16p13.3                      TNFRSF12A                          tumor necrosis factor receptor superfamily member 12A             0.6        0.028        1.3      0.000   0.5    0.218
  NM_001902       1p31.1                         CTH                                    cystathionase cystathionine gamma-lyase                    1.3        0.020        0.5      0.044   0.7    0.194
  NM_003516       1q21.2                     HIST2H2AA3                                         histone cluster 2 H2aa3                            −0.1       0.645        1.2      0.000   0.8    0.194
  L07383          3p21.3                        RPSA                                              ribosomal protein SA                             0.1        0.513        1.2      0.071         
  Y09836                        ORF[\*](#nt101){ref-type="table-fn"}      3 UTR of hypothetical protein ORF1[\*](#nt101){ref-type="table-fn"}      0.7        0.046        1.0      0.011   1.2    0.101
  NM_003712       19p13                        PPAP2C                                    phosphatidic acid phosphatase type 2C                     1.2        0.000        0.9      0.044   1.2    0.000
  NM_014214      18p11.2                        IMPA2                                   inositol myo -1 or 4 -monophosphatase 2                    0.3        0.242        0.0      0.515   1.1    0.000
  Y11158         16p13.3                       SNORA10                                      small nucleolar RNA H/ACA box 10                       −0.1       0.513        1.1      0.000   0.5    0.218
  NM_005311    7p12--p11.2                      GRB10                                   growth factor receptor-bound protein 10                    1.1        0.028        0.7      0.008   0.5    0.218
  AF086251        11q21                         SESN3                                                  sestrin 3                                   0.1        0.534        1.1      0.048   1.1    0.049
  NM_003234        3q29                         TFRC                                         transferrin receptor p90 CD71                         1.1        0.000        0.8      0.025   0.4    0.218
  NM_014061      Xp11.22                       MAGEH1                                         melanoma antigen family H 1                          1.0        0.020       −0.5      0.090   0.0    0.725
  NM_016192       2q32.3                       TMEFF2                     transmembrane protein with EGF-like and 2 follistatin-like domains 2     0.0        0.645        0.3      0.115   1.0    0.049
  NM_003243     1p33--p32                      TGFBR3                                 transforming growth factor beta receptor III                 1.0        0.000        0.1      0.287   0.5    0.236
  U90878       10q22-q26.3                     PDLIM1                                          PDZ and LIM domain 1 elfin                          1.0        0.000        0.4      0.135   0.4    0.287
  AF190900        1q32.1                       KLHL12                                           kelch-like 12 Drosophila                           0.2        0.466        0.7      0.000   1.0    0.194
  NM_002795       17q12                         PSMB3                               proteasome prosome macropain subunit beta type 3               0.5        0.113        0.6      0.063   1.0    0.000
  NM_001814      11q14.2                        CTSC                                                  cathepsin C                                  1.0        0.000                               
  NM_000213       17q25                         ITGB4                                               integrin beta 4                                0.9        0.086       −1.3      0.000   0.1    0.777
  AK021498        7q22.3      FLJ36031[\*](#nt101){ref-type="table-fn"}      Hypothetical protein FLJ36031[\*](#nt101){ref-type="table-fn"}        0.9        0.028       −0.1      0.321   0.1    0.755
  NM_003524       6p21.3                      HIST1H2BH                                          histone cluster 1 H2bh                            0.2        0.380        0.9      0.000   0.2    0.384
  NM_018303       6p25.3                        EXOC2                                         exocyst complex component 2                          0.9        0.000        0.2      0.253   0.2    0.636
  NM_001262        1p32                        CDKN2C                            cyclin-dependent kinase inhibitor 2C p18 inhibits CDK4            0.5        0.211        0.1      0.459   0.9    0.194
  NM_001831     8p21--p12                        CLU                                                   clusterin                                   0.1        0.534        0.9      0.000   0.7    0.049
  NM_003311      11p15.5                       PHLDA2                              pleckstrin homology-like domain family A member 2               0.0        0.624        0.9      0.011   0.8    0.194
  NM_004282    6p12.3-p11.2                     BAG2                                          BCL2-associated athanogene 2                         0.9        0.020        0.4      0.044   0.7    0.194
  NM_001327        Xq28                        CTAG1A                                           cancer/testis antigen 1A                           0.6        0.046        0.9      0.000   0.6    0.194
  AL157449       17q21.33                      PPP1R9B                           protein phosphatase 1 regulatory inhibitor subunit 9B             0.9        0.007        0.9      0.000   0.6    0.218
  AF200348         2p25                         PXDN                                         peroxidasin homolog Drosophila                        −1.2       0.003       −1.3      0.000   0.9    0.064

\*no approved HUGO symbol/name exists for this entry. If present, gene symbol/name from the UNIGENE database is given in alternative.

2log ratio\>0 indicates overexpression in the therapy-refractory subline, compared to parental PC346C.

2log ratio\<0 indicates down-regulation in the therapy-refractory subline.

10.1371/journal.pone.0013500.t002

###### Top 50 genes down-regulated in the therapy-resistant cell lines, expression ratios and SAM q-values.

![](pone.0013500.t002){#pone-0013500-t002-2}

  GenBank       Cytoband                    HUGO symbol                                                 HUGO GeneName                                   PC346DCC   PC346Flu1   PC346Flu2                 
  ----------- ------------- ------------------------------------------- ------------------------------------------------------------------------------ ---------- ----------- ----------- ------- ------ -------
  NM_017935       4q24                         BANK1                                    B-cell scaffold protein with ankyrin repeats 1                    −2.9       0.000       −1.8      0.000   −0.8   0.053
  AF216077        9q32                        COL27A1                                            collagen type XXVII alpha 1                              −2.1       0.000       −2.8      0.000   −1.7   0.053
  NM_014380      Xq22.2                       NGFRAP1                             nerve growth factor receptor TNFRSF16 associated protein 1              −0.2       0.513       −2.5      0.000   −2.7   0.000
  AB042410       1p21.3                        GPR88                                            G protein-coupled receptor 88                             −2.4       0.000       −0.3      0.394   0.8    0.194
  AK026813        7q21                        STEAP2                                six transmembrane epithelial antigen of the prostate 2                −2.3       0.000       −0.8      0.135   −0.8   0.176
  AF188747      19q13.41                       KLK2                                             kallikrein-related peptidase 2                            −2.3       0.000       −0.7      0.063   −0.8   0.053
  NM_012449       7q21                        STEAP1                                six transmembrane epithelial antigen of the prostate 1                −2.3       0.000       −0.9      0.036   −0.5   0.236
  NM_003307      21q22.3                       TRPM2                           transient receptor potential cation channel subfamily M member 2           −2.1       0.000        0.0      0.536   −0.1   0.725
  AB020968       6q22.2                       MARCKS                                myristoylated alanine-rich protein kinase C substrate                 −1.6       0.000       −2.0      0.000   −1.3   0.053
  M26663        19q13.41                       KLK3                                             kallikrein-related peptidase 3                            −2.0       0.009        0.0      0.207   −0.4   0.392
  NM_004117    6p21.3-21.2                     FKBP5                                               FK506 binding protein 5                                −2.0       0.000        0.1      0.459   0.4    0.218
  NM_001359      8q21.3                        DECR1                                      2 4-dienoyl CoA reductase 1 mitochondrial                       −1.9       0.000       −1.1      0.000   −1.6   0.053
  NM_014333      11q23.2                       CADM1                                               cell adhesion molecule 1                               −1.0       0.000       −1.9      0.000   −0.1   0.725
  AK026331        2q35         CHPF[\*](#nt104){ref-type="table-fn"}           Chondroitin polymerizing factor[\*](#nt104){ref-type="table-fn"}           −1.7       0.000       −0.8      0.048   −0.2   0.678
  AB020637        11q21                       ENDOD1                                           endonuclease domain containing 1                           −1.7       0.000       −0.4      0.160   0.2    0.678
  NM_012116      19q13.2                       CBLC                              Cas-Br-M murine ecotropic retroviral transforming sequence c             −1.6       0.000       −1.2      0.000   −0.4   0.218
  X15667                       GPRP[\*](#nt104){ref-type="table-fn"}     Glutathione peroxidase-related protein GPRP[\*](#nt104){ref-type="table-fn"}     −1.6       0.022        0.2      0.185   −0.8   0.053
  NM_006167       8p21                        NKX3-1                                                    NK3 homeobox 1                                    −1.6       0.003       −0.1      0.459   −0.3   0.413
  NM_006006      11q23.1                      ZBTB16                                       zinc finger and BTB domain containing 16                       −1.6       0.003        0.1      0.444   0.3    0.328
  NM_003278    3p22-p21.3                     CLEC3B                                        C-type lectin domain family 3 member B                        −1.5       0.005       −1.3      0.000   −1.3   0.084
  AL049963      4q22-q24                      SLC39A8                                 solute carrier family 39 zinc transporter member 8                  −1.5       0.000       −1.4      0.000   −0.9   0.053
  AK000216       3p21.31     FLJ20209[\*](#nt104){ref-type="table-fn"}          Hypothetical protein FLJ20209[\*](#nt104){ref-type="table-fn"}            −1.5       0.000       −0.7      0.115   −0.7   0.084
  AK000028        4q24       LOC90024[\*](#nt104){ref-type="table-fn"}              Hypothetical LOC90024[\*](#nt104){ref-type="table-fn"}                −1.5       0.000       −0.7      0.000   −0.5   0.120
  NM_007011      15q26.1                       ABHD2                                           abhydrolase domain containing 2                            −1.5       0.000       −1.1      0.032   0.1    0.573
  AK024917        1p22                         DDAH1                                      dimethylarginine dimethylaminohydrolase 1                       −0.3       0.380       −1.5      0.000   0.1    0.760
  AF252283        13q21                        KLHL1                                               kelch-like 1 Drosophila                                −1.5       0.000        0.5      0.115   0.1    0.738
  X75684        3q21-q25                      TM4SF1                                        transmembrane 4 L six family member 1                         0.6        0.211       −1.5      0.000   0.5    0.194
  AL122055        6q21                        CDC2L6                                        cell division cycle 2-like 6 CDK8-like                        −1.4       0.000       −1.3      0.000   −1.2   0.000
  NM_000944     4q21-q24                      PPP3CA                          protein phosphatase 3 formerly 2B catalytic subunit alpha isoform           −1.4       0.028       −1.2      0.000   −1.0   0.084
  NM_016598      3p21.31                      ZDHHC3                                          zinc finger DHHC-type containing 3                          −1.4       0.003       −1.1      0.000   −0.9   0.053
  NM_002151    19q11-q13.2                      HPN                                         hepsin transmembrane protease serine 1                        −1.0       0.000       −0.9      0.000   −1.4   0.053
  NM_001311     14q32.33                       CRIP1                                          cysteine-rich protein 1 intestinal                          −1.4       0.018        0.4      0.101   −0.9   0.115
  AL050367        10p13                      C10orf38                                        chromosome 10 open reading frame 38                          0.1        0.380       −1.4      0.000   −0.6   0.084
  NM_005864    14q11.2-q12                      EFS                                           embryonal Fyn-associated substrate                          −1.4       0.009        0.4      0.135   −0.6   0.064
  NM_005510      6p21.3                        DOM3Z                                              dom-3 homolog Z C. elegans                              0.5        0.211        0.1      0.422   −1.4   0.053
  NM_019005     7p22-p21     FLJ20323[\*](#nt104){ref-type="table-fn"}          Hypothetical protein FLJ20323[\*](#nt104){ref-type="table-fn"}            −0.9       0.000       −1.3      0.000   −0.6   0.134
  AK026517        11p12                         EHF                                                 ets homologous factor                                 −0.7       0.028       −1.3      0.000   −0.6   0.309
  AF271070      12q13.11                      SLC38A1                                         solute carrier family 38 member 1                           −1.3       0.000       −0.7      0.044   −0.2   0.678
  AF200348        2p25                         PXDN                                             peroxidasin homolog Drosophila                            −1.2       0.003       −1.3      0.000   0.9    0.064
  NM_003255       17q25                        TIMP2                                          TIMP metallopeptidase inhibitor 2                           0.6        0.028       −1.3      0.031   −0.2   0.678
  L29496       Xq11.2-q12                       AR                                                    androgen receptor                                   −1.3       0.018        0.9      0.000   −0.3   0.194
  NM_000213       17q25                        ITGB4                                                   integrin beta 4                                    0.9        0.086       −1.3      0.000   0.1    0.777
  D80010         2p25.1                        LPIN1                                                       lipin 1                                        −1.2       0.000       −1.1      0.015   −0.9   0.053
  NM_007173      11q14.1                      PRSS23                                                  protease serine 23                                  −1.2       0.018       −0.9      0.021   −0.9   0.101
  NM_002165       20q11                         ID1                         inhibitor of DNA binding 1 dominant negative helix-loop-helix protein         −1.2       0.018                         −0.6   0.500
  NM_017860      1q21.2                       C1orf56                                         chromosome 1 open reading frame 56                          −0.5       0.037       −1.2      0.000   −0.6   0.053
  NM_004457     2q34-q35                       ACSL3                                    acyl-CoA synthetase long-chain family member 3                    −1.2       0.009       −0.7      0.025   −0.3   0.101
  NM_005045       7q22                         RELN                                                         reelin                                        −1.2       0.003       −0.6      0.101   −0.2   0.714
  NM_005544       2q36                         IRS1                                              insulin receptor substrate 1                             −1.2       0.020       −0.1      0.394   0.0    0.714
  AK024495       11p15.5                      LRRC56                                          leucine rich repeat containing 56                           −1.2       0.000        0.2      0.321   0.5    0.218

\*no approved HUGO symbol/name exists for this entry. If present, gene symbol/name from the UNIGENE database is given in alternative.

2log ratio\>0 indicates overexpression in the therapy-refractory subline, compared to parental PC346C.

2log ratio\<0 indicates down-regulation in the therapy-refractory subline.

10.1371/journal.pone.0013500.t003

###### Chromosomal clustering of the differentially expressed transcripts.
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  Cell line    \#genes regulated   up/down regulated   Cytoband   \#genes cytoband[\*](#nt108){ref-type="table-fn"}   Bonferroni p-value
  ----------- ------------------- ------------------- ---------- --------------------------------------------------- --------------------
  PC346DCC             7                 down          4q21-24                           56                                 0.003
  PC346DCC             9                 down          5q11-23                           130                                0.028
  PC346DCC             6                 down          6q14-23                           65                                 0.026
  PC346DCC             8                 down          8p11-22                           74                                 0.003
  PC346DCC            10                 down          8q11-24                           131                                0.006
  PC346Flu1            6                 down          11p11-15                          92                                 0.068
  PC346Flu2           14                  up              18                             109                               \<0.0001

p-values determined by Fisher\'s exact test with Bonferroni correction for multiple testing.

\*number of genes located in the cytoband that are expressed by the indicated cell line.

AR pathway is down-regulated in PC346DCC {#s3b}
----------------------------------------

To investigate the activation state of the AR pathway in the PC346DCC, PC346Flu1 and PC346Flu2, the SRS database was used to link and compare our present data with a previously established androgen-response gene signature ([Fig. 2A](#pone-0013500-g002){ref-type="fig"}). This androgen-response signature was determined by expression microarray analysis, after stimulation of the different PC346 cell lines with the synthetic androgen R1881 or the antiandrogen hydroxyflutamide ([Table S4](#pone.0013500.s004){ref-type="supplementary-material"}). Of the 487 differentially-regulated transcripts in the therapy-resistant sublines, only 27 were AR target genes (\<6%), indicating that other genes and pathways are also involved in hormone-therapy refractory proliferation of these sublines. Furthermore, AR target genes were down-regulated in PC346DCC (p-value  = 10^−7^), whereas their expression in PC346Flu1 and PC346Flu2 was not significantly affected ([Fig. 2B](#pone-0013500-g002){ref-type="fig"}). However, although not statistically significant for the AR pathway as a whole, PC346Flu1 and PC346Flu2 did show lower induction of some androgen-responsive genes such as KLK2, STEAP1, STEAP2 and EHF.

![Activation state of the AR pathway in the PC346DCC, PC346Flu1 and PC346Flu2.\
Differentially-expressed genes in PC346 hormone-refractory sublines versus parental PC346C were linked to a previously established androgen-response gene signature (see Materials and [Methods](#s2){ref-type="sec"} section). (A) Heat-map representation of androgen-responsive genes deregulated in any of the PC346 hormone-refractory sublines. Color scheme as described in [Fig. 1](#pone-0013500-g001){ref-type="fig"}. (B) Venn-diagram and respective statistics.](pone.0013500.g002){#pone-0013500-g002}

Gene ontology and pathway analysis identifies cancer signature {#s3c}
--------------------------------------------------------------

The selected 487-gene signature was classified according to Gene Ontology (GO) Biological Processes using the Database for Annotation, Visualization and Integrated Discovery (DAVID) [@pone.0013500-Dennis1], [@pone.0013500-Huangda1]. Annotation clustering analysis showed enrichment in categories involved in organ development, reproductive system differentiation, cellular growth, differentiation and apoptosis ([Table 4](#pone-0013500-t004){ref-type="table"}). Ingenuity Pathway Analysis was used to identify enrichment in "diseases and disorders", "molecular and cellular functions", and to search for intrinsic pathways/networks within the selected gene sets ([www.ingenuity.com](http://www.ingenuity.com)). Cancer and reproductive system disease were ranked in the top 3 of "diseases and disorders", which logically confirmed the enrichment of genes associated with PCa, such as hepsin, clusterin, vitamin D receptor, trefoil factor 3, tumor protein D52, the AR itself and several of its target genes ([Fig. 3A and 3B](#pone-0013500-g003){ref-type="fig"}, respectively). Furthermore, we used Network analysis to screen the 276-gene signature of PC346DCC for potential alternative growth pathways that could be involved in bypassing the AR signaling. Interestingly, signaling via growth-hormone receptor (GHR), insulin receptor (INSR) and epidermal growth factor receptor was among the top 10 Networks (score  = 20) showing deregulation in PC346DCC ([Fig. 3C](#pone-0013500-g003){ref-type="fig"}).

![Biological processes deregulated in the hormone-refractory sublines.\
Top 5 biological functions enriched in the therapy-resistant sublines: (A) diseases and disorders, (B) molecular and cellular functions. (C) Example of Network analysis for PC346DCC showing deregulation of hormone and growth-factor receptor signaling: up-regulated genes are represented in red and repressed genes in green. Analysis was performed using Ingenuity Pathway Analysis software ([www.ingenuity.com](http://www.ingenuity.com)).](pone.0013500.g003){#pone-0013500-g003}

10.1371/journal.pone.0013500.t004

###### Biological processes significantly enriched in the therapy-resistant gene signature.
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  --------------------------- ------------------------------------------------------------ ----------- -------------
  **Annotation Cluster 1**                     **Enrichment Score: 4.42**                   **count**   **P value**
                                          multicellular organismal development                 86         1.8E-05
                                            anatomical structure development                   78         7.7E-05
                                                   system development                          68         3.9E-05
  **Annotation Cluster 2**                     **Enrichment Score: 4.24**                   **count**   **P value**
                                                  cell differentiation                         69         7.7E-05
                                                    cell development                           53         3.1E-05
  **Annotation Cluster 3**                     **Enrichment Score: 4.09**                   **count**   **P value**
                                                       apoptosis                               38         4.1E-05
                                                 programmed cell death                         38         5.0E-05
  **Annotation Cluster 4**                     **Enrichment Score: 2.68**                   **count**   **P value**
                                             regulation of phosphorylation                      8         1.7E-03
                                       regulation of phosphate metabolic process                8         2.3E-03
  **Annotation Cluster 5**                     **Enrichment Score: 2.67**                   **count**   **P value**
                                      amino acid and derivative metabolic process              21         5.8E-04
                                                amine metabolic process                        21         6.0E-03
                                          nitrogen compound metabolic process                  22         6.7E-03
  **Annotation Cluster 6**                     **Enrichment Score: 2.15**                   **count**   **P value**
                                            regulation of biological process                   134        3.0E-03
                                             regulation of cellular process                    124        1.4E-02
                                             regulation of gene expression                     63         6.7E-02
  **Annotation Cluster 7**                     **Enrichment Score: 2.15**                   **count**   **P value**
                                                      neurogenesis                             16         7.0E-03
                                                 neuron differentiation                        14         6.2E-03
  **Annotation Cluster 8**                     **Enrichment Score: 2.03**                   **count**   **P value**
                                            cellular lipid metabolic process                   29         3.8E-03
                                                lipid metabolic process                        28         1.6E-03
  **Annotation Cluster 9**                     **Enrichment Score: 1.82**                   **count**   **P value**
                                                     DNA packaging                             16         8.9E-03
                               establishment and/or maintenance of chromatin architecture      15         1.7E-02
                                         chromosome organization and biogenesis                17         2.3E-02
                                           chromatin assembly or disassembly                    9         2.1E-02
                                                  nucleosome assembly                           7         1.8E-02
  **Annotation Cluster 10**                    **Enrichment Score: 1.70**                   **count**   **P value**
                                     development of primary sexual characteristics              7         2.0E-02
                                                  sex differentiation                           6         1.8E-02
                                           reproductive developmental process                   6         2.2E-02
                                                   gonad development                            5         4.9E-02
  **Annotation Cluster 11**                    **Enrichment Score: 1.42**                   **count**   **P value**
                                                         growth                                12         8.3E-02
                                                regulation of cell size                        11         1.8E-02
                                                      cell growth                              10         3.7E-02
  --------------------------- ------------------------------------------------------------ ----------- -------------

Integrative analysis reveals genes deregulated in prostate cancer progression {#s3d}
-----------------------------------------------------------------------------

To identify genes modulated in PCa that could explain hormone-therapy refractory growth through bypass of the AR pathway, we linked the 276-gene signature from PC346DCC with data from seven PCa microarray studies published previously ([Table 5](#pone-0013500-t005){ref-type="table"}) [@pone.0013500-Tomlins1], [@pone.0013500-Best1], [@pone.0013500-Chandran1], [@pone.0013500-Lapointe1], [@pone.0013500-Tamura1], [@pone.0013500-Varambally1], [@pone.0013500-Yu1]. Only genes present in at least 5/7 databases (209 genes) and deregulated in at least 3/7 (111 genes) were included for further analysis. Hierarchical clustering performed on the signature genes (first column), next to primary cancer vs. normal prostate (second column), metastatic cancer vs. primary cancer (third column), and finally hormone-refractory vs. hormone-naïve disease (fourth column), is shown in [Fig. 4](#pone-0013500-g004){ref-type="fig"}. Approximately 30% of the genes differentially expressed in PC346DCC were found to be consistently deregulated in metastatic PCa compared to organ-confined disease.

![Expression of the androgen-independent PC346DCC signature genes in prostate cancer samples from patient tumors.\
The 276-gene signature from PC346DCC was linked to data from 7 prostate cancer microarray databases of primary (Lapointe, Varambally, Tomlins, Yu), metastatic (Chandran, Lapointe, Varambally, Tomlins, Yu) and hormone-therapy refractory tumors (Tamura, Tomlins and Best). Only genes present in at least 5/7 databases (209 genes) and deregulated in at least 3/7 (111 genes) were included in the analysis. Heat-map representation of (A) 72 overexpressed and (B) 39 repressed genes in PC346DCC. (C) Deregulated genes selected for further qPCR analysis. Color scheme as described in [Fig. 1](#pone-0013500-g001){ref-type="fig"}. Grey squares indicate missing data, either due to low expression levels, poor data quality or absence of probes for the respective transcript in the array platform used for the study. PC-NAP: prostate cancer minus normal adjacent prostate; MET-PC: metastasis minus primary prostate tumors; HR-HN: hormone-therapy refractory minus hormone-naïve tumors.](pone.0013500.g004){#pone-0013500-g004}

10.1371/journal.pone.0013500.t005

###### Description of prostate cancer databases linked via SRS.
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  First Author                           Reference samples                                      Test samples
  ----------------------- ------------------------------------------------ -------------------------------------------------------
  Best (2005)^29^                10 hormone-naive prostate cancers              10 hormone-refractory primary prostate tumors
  Chandran (2007)^30^            64 primary prostate tumor samples          24 hormone-refractory metastatic samples (4 patients)
  Lapointe (2004)^31^       41 benign prostate tissue adjacent to cancer              62 primary prostate tumor samples
                                                                                           9 lymph node metastasis
  Tamura (2007)^32^              10 hormone-naive prostate cancers           18 hormone-refractory primary and metastatic tumors
  Tomlins (2007)^14^       15 benign epithelial tissue adjacent to cancer             30 primary prostate tumor samples
                                                                            3 hormone-naive and 17 hormone-refractory metastasis
  Varambally (2005)^33^              5 benign prostate tissues                     5 clinically localized prostate cancers
  Yu (2004)^34^             60 benign prostate tissue adjacent to cancer           5 hormone-refractory metastatic samples
                               23 disease free donor prostate tissue                     62 primary prostate tumors
                                                                                      24 hormone-refractory metastasis

TWIST1, DKK3 and VAV3 as markers for disease diagnosis and prognosis {#s3e}
--------------------------------------------------------------------

Based on their recognized pathological functions and consistent deregulation in multiple PCa databases, twist homolog 1 (TWIST1), vav 3 guanine nucleotide exchange factor (VAV3) and dickkopf homolog 3 (DKK3) were selected for their potential role in the bypass of the AR pathway. In this manner, TWIST1 and VAV3 are putative oncogenes involved in growth hormone signaling, as revealed by Ingenuity Pathway Analysis ([Fig. 3C](#pone-0013500-g003){ref-type="fig"}). On the other hand, DKK3 is a tumor suppressor, showing strong down-regulation in the datasets from Chandran *et al.*, Lapointe *et al.* and Varambally *et al.* ([Fig. 4C](#pone-0013500-g004){ref-type="fig"}). Whereas TWIST1 showed consistent up-regulation in primary and metastatic PCa datasets from Varambally *et al.*, Yu *et al.*, Lapointe *et al.* and Chandran *et al.*, VAV3 was down-regulated in primary tumors followed by up-regulation in metastasis ([Fig. 4C](#pone-0013500-g004){ref-type="fig"}).

Quantitative RT-PCR was performed on an independent set of prostate samples, obtained by radical prostatectomy or transurethral resection of the prostate of patients being operated at Erasmus MC clinic. This panel contained 21 benign prostate tissue samples and 74 adenocarcinomas at different disease stages. Quantitative PCR analysis showed up-regulation of TWIST1 in primary PCa samples and lymph node metastasis (P-value  = 0.0001 and 0.002, respectively). No difference was observed between hormone-refractory (HRPC) and hormone-naïve tumors (HNPC) ([Fig. 5A](#pone-0013500-g005){ref-type="fig"}). DKK3 expression was significantly decreased in PCa and lymph node metastasis (P-value ≤0.0001), although no difference was observed during progression from organ-confined to metastatic or hormone-refractory disease ([Fig. 5B](#pone-0013500-g005){ref-type="fig"}). VAV3 expression decreased gradually during PCa progression, with the lowest levels observed in metastatic prostate tumors (P-value  = 0.0001 for Post linear-trend test) and hormone-refractory samples (P-value  = 0.005 for HNPC vs. HRPC; [Fig. 5C](#pone-0013500-g005){ref-type="fig"}). Lymph node samples were removed from the VAV3 analysis in [Fig. 5C](#pone-0013500-g005){ref-type="fig"}, because VAV3 was highly expressed in normal lymph node compared to normal prostate tissues (data not shown). In these settings, the presence of remnants of normal lymph node tissue can lead to over-estimation of the real VAV3 quantity in lymph node metastasis. Kaplan-Meier analysis showed a direct correlation between VAV3 expression and metastasis-free survival (P-value  = 0.004 for Logrank trend test; [Fig. 5D](#pone-0013500-g005){ref-type="fig"}).

![Quantitative RT-PCR analysis of TWIST1, DKK3 and VAV3 in an independent set of prostate samples.\
Prostate tumor samples were obtained by radical prostatectomy or transurethral resection of the prostate of patients being operated at Erasmus MC clinic. This panel contains 21 benign prostate tissue samples and 74 adenocarcinomas at different disease stages. (A) TWIST1; (B) DKK3; (C) VAV3 expression in prostate samples; (D) VAV3 metastasis-free survival analysis. NAP: normal adjacent prostate; PC: primary prostate cancer; LNmet: lymph node metastasis; PC-Met: non-progressive organ-confine prostate cancer; PC+Met: primary tumor from progressive prostate cancer that either had or developed metastasis during subsequent follow-up; HN: hormone-naïve; HR: hormone-therapy refractory; (\*) p-value ≤0.0001 and (\*\*) p-value ≤0.005 using Mann-Whitney two-tailed test. (\*\*\*) p-value ≤0.0001 with Post linear-trend test.](pone.0013500.g005){#pone-0013500-g005}

Discussion {#s4}
==========

In the present study we used microarray analysis to identify differences in the gene expression pattern of the androgen-responsive PC346C cell line and its therapy-resistant sublines: PC346DCC, PC346Flu1 and PC346Flu2. This analysis detected 487 transcripts differentially regulated in the hormone-therapy refractory cells versus the parental PC346C. Many of these were common to all therapy-resistant sublines, despite the different AR pathway modifications, suggesting similar growth enhancing adaptations ([Fig. 1](#pone-0013500-g001){ref-type="fig"}). These shared genes could be divided in four main categories: regulation of cell cycle progression and proliferation (ex. HPN, NDN, ATR, ABL2, DHRS2), development and cellular differentiation (CLEC3B, KCNJ8, ADAM29, DNMT3A), fatty acid and steroid metabolism (LPIN1, DECR1, ACSL3) and intracellular signaling transduction (PPAP2C, PPP3CA, PRSS23, GRB10, SIPA1L2). Interestingly, 40 of the genes down-regulated in PC346DCC clustered in just four genomic locations: 4q21-24 (7 genes), 5q11-23 (9 genes), 6q14-23 (6 genes) and chr8 (18 genes). This is more than would be expected by chance. Also 6 genes down-regulated in PC346Flu1 and 14 up-regulated genes in PC346Flu2 clustered at 11q11-15 and chr18, respectively ([Table 3](#pone-0013500-t003){ref-type="table"}). Duplication of chromosome 18 and loss of 8p has been previously reported in PC346Flu2 and PC346DCC, respectively, and may explain the clustering observed at these loci [@pone.0013500-Marques1]. However, no evidence of chromosomal amplifications or deletions was detected at the other loci mentioned. A possible explanation is that epigenetic mechanisms, such as promotor methylation or histone modifications, may be involved in the transcriptional regulation of these large chromosomal regions. Indeed, expression of DNA methyltransferase DNMT3A and histone deacetylase HDAC6 was altered in PC346DCC, supporting this hypothesis. Nevertheless, losses at 4q, 5q, 6q, 8p and 11p have been frequently reported in PCa specimens and these loci are suspected of harbouring potential tumor suppressor genes [@pone.0013500-Dong1], [@pone.0013500-Verma1].

Previously, we have shown that PC346DCC, PC346Flu1 and PC346Flu2 display different AR modifications that resulted in distinct mechanisms of hormone-therapy refractory growth [@pone.0013500-Marques1]. PC346DCC revealed very low levels of the AR and its target gene prostate specific antigen (PSA), and was insensitive to androgen stimulation in growth assays, promotor transactivation assays and expression microarray profiling (unpublished data) [@pone.0013500-Marques1]. These results suggest that the AR pathway has been bypassed and is not essential for the growth of PC346DCC cells. The present study further substantiates this hypothesis by showing a strong down-regulation of AR target genes compared to the parental PC346C ([Fig. 2](#pone-0013500-g002){ref-type="fig"}). PC346Flu1, on the other hand, expresses high levels of the AR and previously showed a "super-activation" of this receptor in response to androgens, both in transactivation assays as in expression microarray analysis (unpublished data) [@pone.0013500-Marques1]. Interestingly, the proliferation of this subline is inhibited by physiological concentration of androgens, and is optimal in the absence of this ligand. A possible explanation for this growth suppressive effect is that the "super-activation" of the AR by androgens in PC346Flu1 may be tilting the balance towards cellular differentiation [@pone.0013500-Cinar1], [@pone.0013500-Tararova1]. It is worth noting how few AR target genes are deregulated in PC346Flu1 versus the parental PC346C ([Fig. 2](#pone-0013500-g002){ref-type="fig"}). This suggests that the AR pathway remained active in the PC346Flu1 cells cultured in androgen-depleted medium supplemented with AR antagonist hydroxyflutamide. The few AR target genes that were differentially expressed in PC346Flu1 include EHF, NFIB and HLX, which are involved in development and differentiation processes. The third therapy-resistant subline studied here, PC346Flu2, carries the T877A AR mutation, well known for causing broadened receptor activation by non-androgenic ligands, including flutamide [@pone.0013500-Veldscholte1]. Consistent with the presence of this "promiscuous" AR, the growth of PC346Flu2, as well as expression of AR target genes, are stimulated by both the synthetic androgen R1881 and the antiandrogen hydroxyflutamide (unpublished data) [@pone.0013500-Marques1]. In PC346Flu2, the presence of the T877A AR mutation allows for the maintenance of AR activity in the selection medium supplemented with 1 µM hydroxyflutamide. This is further substantiated in the present study by the observation that PC346Flu2 is the least divergent of the therapy-resistant sublines, with no more than 127 differentially regulated transcripts compared to the parental PC346C ([Fig. 1](#pone-0013500-g001){ref-type="fig"}).

Of the 487 transcripts differentially expressed between androgen-responsive PC346C cells and the therapy-resistant sublines only a few (∼5%) were AR-regulated genes. These results indicate that the gene expression differences observed are not largely explained by R1881 activating the AR transcriptional program in PC346C cells. Expression of AR-regulated cell cycle genes, such as A-, B- and D-type cyclins, cyclin-dependent kinases (CDK1, CDK2, CDK4, CDK6) and cyclin-dependent kinase inhibitors (CDKN1B, CDKN2A, CDKN2B), was generally unaffected [@pone.0013500-Chen1], [@pone.0013500-Lu1], [@pone.0013500-Gregory1], [@pone.0013500-Taneja1], [@pone.0013500-Xu1], [@pone.0013500-Lu2]. Cyclin D1 (CCND1) was the only cyclin found to be deregulated, with a 2-fold lower expression level in all three therapy-resistant sublines. However, apart from its role in cell cycle transitions, CCND1 is also a potent inhibitor of AR activity [@pone.0013500-PetreDraviam1]. Since CCND1 expression is induced by androgens, higher expression in PC346C may reflect the R1881 supplementation in this cell line [@pone.0013500-Fribourg1]. On the other hand, lower expression of CCND1 in the therapy-resistant sublines, in particular PC346Flu1 and PC346Flu2, may contribute to the maintenance of AR activity under selection conditions. Finally, one must keep in mind that cyclins and other cell cycle genes are mainly regulated during cell division through post-transcriptional mechanisms, including protein degradation, localization and phosphorylation [@pone.0013500-Xu1], [@pone.0013500-Balk1].

Both PC346Flu1 and PC346Flu2 sublines have an active AR and acquired hormone-therapy refractory proliferation through adaptations of the AR pathway. Therefore, to study alternative survival and growth pathways independent of the AR we further focused on the expression profile of PC346DCC cells. The Ingenuity Pathway Analysis program was used to screen the 276-gene signature of PC346DCC for potential gene Networks that could be involved in bypassing the AR signaling. Among the top 10 Networks, the signaling pathway via growth-hormone receptor (GHR), insulin receptor (INSR) and epidermal growth factor receptor (EGFR) as a potential candidate emerged ([Fig. 3C](#pone-0013500-g003){ref-type="fig"}). These receptors are not themselves deregulated in PC346DCC but several partners of this signaling pathway were, including VAV3 and TWIST1. VAV3 and TWIST1 are potential oncogenes, and while VAV3 can interact with and cross-activate signaling via hormone and growth receptors, expression of TWIST1 is in turn stimulated by EGF and IGF1 [@pone.0013500-Lo1], [@pone.0013500-Dupont1], [@pone.0013500-Zeng1], [@pone.0013500-Moores1]. The effect of peptide growth factors on androgen independent proliferation of prostate cancer cells is mainly mediated via the Ras/MAPK, PI3K/AKT and STAT3 signaling cascades [@pone.0013500-Wang1], [@pone.0013500-Culig2]. These signaling pathways may directly activate transcription of genes involved in cell survival, proliferation and migration, but may also indirectly activate the AR pathway in a ligand-independent manner. In the absence of androgens, MAPK and AKT kinases may induce AR phosphorylation and activation, whereas STAT3 can bind ligand-free AR and facilitate its translocation to the nucleus. Thus peptide growth factors may function as alternative survival/growth pathways, for example in the subgroup of AR negative prostate tumors, and/or as an adaptation of AR pathway by preserving AR activity under androgen ablation conditions. Recent reports have implicated Src, a member of the Src-family kinases, in the proliferation of hormone-refractory tumors. Src kinase was found to be overexpressed in prostate cancer, where Src inhibitors decreased proliferation and invasion of cell lines and xenografts [@pone.0013500-Fizazi1], [@pone.0013500-Asim1]. Src-family kinases are nonreceptor protein tyrosine kinases responsible for signal transduction in many cellular and oncogenic processes. Src kinases are activated upon binding to cell surface receptors, such as G-protein coupled receptors, growth factor receptors and integrins, or other intracellular protein kinases [@pone.0013500-Fizazi1], [@pone.0013500-Tatarov1]. In turn, activated Src kinases signal via the MAPK, PI3K, STAT3 and FAK pathways. Src kinases are also activators of VAV3 and TWIST1, either directly by phosphorylating and releasing inhibitory tyrosine Y173 of VAV3, or indirectly by activating STAT3, a transcription activator for TWIST1 [@pone.0013500-Colomba1], [@pone.0013500-Cheng1]. These results link the MAPK, PI3K, STAT3 and Src kinase signaling to growth factor pathways and to our candidate genes selected for hormone-refractory progression. Both VAV3 and TWIST1 are overexpressed in PC346DCC cells, and survey of 7 previous microarray studies revealed a consistent up-regulation in metastatic patient material ([Fig. 4C](#pone-0013500-g004){ref-type="fig"}). Another interesting candidate gene for the bypass of the AR pathway was the DKK3 tumor suppressor, which was down-regulated in PC346DCC and multiple databases of primary and metastatic tumors ([Fig. 4C](#pone-0013500-g004){ref-type="fig"}). While compelling evidence links these genes to PCa pathogenesis, it is not known whether TWIST1, VAV3 or the tumor suppressor DKK3 may have a functional role in developing resistance to hormonal therapy.

TWIST1 is a helix-loop-helix transcription factor, regulator of embryonic morphogenesis, and highly expressed in many types of human cancer [@pone.0013500-Puisieux1]. The role of TWIST1 as a potential oncogene was first suggested through a functional screen for cDNAs that could counteract the pro-apoptotic effects of the MYC oncogene. In that study, TWIST1 expression bypassed P53-induced growth arrest and promoted colony formation, consistent with a potential role as oncoproteins [@pone.0013500-Maestro1]. Yang *et al.* showed that suppression of TWIST1 expression in highly metastatic mammary carcinoma cells specifically inhibited their ability to metastasise to the lung, while ectopic expression resulted in activation of mesenchymal markers and induction of cell motility [@pone.0013500-Yang1]. Previous studies also implicated TWIST1 in the development and progression of PCa, showing that its expression was up-regulated in prostate adenocarcinomas and correlated with Gleason grading and increased metastatic potential [@pone.0013500-Yuen1], [@pone.0013500-Kwok1]. Furthermore, inactivation of TWIST1, through small interfering RNA, induced growth arrest and suppressed migration and invasion abilities in androgen-independent PCa cell lines DU145 and PC3 [@pone.0013500-Kwok1], [@pone.0013500-Kwok2]. We quantified TWIST1 expression in a panel of patient derived material, comprising 21 normal prostate samples (adjacent to cancer), 74 primary prostate tumors, of which 9 hormone-refractory samples, and 13 lymph node metastasis. Among the primary tumors are 59 samples of early organ-confined disease, 9 samples of invasive tumors that eventually developed metastasis during follow-up and 6 tumors with lymph node and/or distant metastasis at the time of operation. Quantitative PCR confirmed overexpression of TWIST1 in primary PCa samples and lymph node metastasis ([Fig. 5A](#pone-0013500-g005){ref-type="fig"}). In this patient cohort, TWIST1 expression could not predict progression, as it did not differ between non-progressive organ-confined tumors and primary cancers that eventually developed metastasis. Furthermore, TWIST1 expression was not increased in hormone-refractory tumors when compared to hormone-naïve samples, suggesting that TWIST1 overexpression alone may not be enough to confer hormone-refractory growth. However, since TWIST1 is strongly up-regulated in PCa samples it may still be useful as a cancer marker or therapeutical target.

VAV3 is a member of the VAV family of oncoproteins, GTPase guanine nucleotide exchange factors that regulate receptor protein tyrosine kinases. It can be activated upon engagement of growth factor receptors, such as EGFR, PDGFR, INSR or IGF1R, and in turn activate downstream PLC and PI3K signaling pathways [@pone.0013500-Zeng1], [@pone.0013500-Moores1], [@pone.0013500-Movilla1]. Previous studies have implicated VAV3 in the pathogenesis of the prostate: (i) VAV3 expression has been detected in the prostate, at increased levels in cancer cells [@pone.0013500-Dong2]; (ii) it has been shown to interact with the AR pathway, stimulating ligand-independent cell growth in LNCAP-hormone-refractory cells [@pone.0013500-Dong2], [@pone.0013500-Lyons1], and (iii) targeting of constitutively active VAV3 expression to the prostate induced PCa in mice [@pone.0013500-Liu1]. Surprisingly, in our patient derived samples, VAV3 expression decreased gradually during PCa progression, with the lowest levels in metastatic and hormone-refractory samples ([Fig. 5C](#pone-0013500-g005){ref-type="fig"}). Furthermore, Kaplan-Meier analysis showed a direct correlation between VAV3 expression levels and metastasis-free survival ([Fig. 5D](#pone-0013500-g005){ref-type="fig"}). These results encourage the use of VAV3 as a potential prognosis marker in PCa, and provide a possible mechanism for the bypass of AR pathway in therapy-refractory tumors. However, the decrease of VAV3 expression in PCa progression was unexpected, considering the function of VAV3 as a potential oncogene. In fact, VAV3 has three transcript variants, the full length VAV3, the VAV3 beta isoform and the truncated VAV3.1 variant, which has no guanine nucleotide exchange activity (GEF) due to lack of N-terminal domains [@pone.0013500-Zeng1], [@pone.0013500-Movilla1], [@pone.0013500-Trenkle1]. The truncated transcript is expressed in many tissues and is the major variant in the prostate [@pone.0013500-Zeng1], [@pone.0013500-Trenkle1]. Because the effect of VAV3 on cell division and AR activation is dependent on GEF activity, this variant is not oncogenic and has most likely a different function than the full-length protein. It was proposed that this VAV3.1 variant may function as a dominant negative of other VAV family members [@pone.0013500-Zeng1], [@pone.0013500-Trenkle1]. In this context, a decrease in the VAV3.1 variant could actually result in increased activity of oncogenic VAV proteins. The TaqMan primers that we used in the quantitative-PCR target the last 2 of the 27 VAV3 exons, being possible that this assay preferentially captures the short C-terminal VAV3.1 transcript. Clearly, it is essential to characterize the different VAV3 variants in the prostate and evaluate how the balance of these is affected during PCa progression, before one can consider its use in the clinic. These results exemplify the limitation of large-scale expression profiling assays that rely on a single probe per gene. Ultimately, to investigate gene expression in the context of human disease, it may not be enough to quantify the major known transcript but one may need to consider the different isoforms and how these variants interact with each other. In the near future we expect to be able to answer how different splice variants from the same gene (including VAV3) can relate to PCa, using exon microarray analysis of the patient tumor material.

DKK3 is part of an evolutionary conserved gene family encoding secreted proteins, which play an important role in vertebrate embryonic development as antagonists of Wnt/beta-catenin signaling. DKKs are further implicated in bone formation and bone disease, Alzheimer\'s and cancer [@pone.0013500-Niehrs1]. DKK3 was proposed to function as a tumor suppressor since it was found to be down-regulated in a number of malignancies including kidney, bladder, lung, pancreas and prostate cancer [@pone.0013500-Hsieh1]. Reduced DKK3 expression may, at least in part, be explained by promotor methylation, which has been detected in various cancers, including over 65% of prostate tumors [@pone.0013500-Lodygin1]. Additional reports showed consistent reduction of DKK3 expression in prostate adenocarcinomas, particularly those with a high Gleason grade [@pone.0013500-Kawano1], [@pone.0013500-Zenzmaier1]. Moreover, small interfering RNA-mediated down-regulation of DKK3 enhanced cell cycle progression and disrupted three-dimensional acinar morphogenesis in RWPE-1 prostate epithelial cells [@pone.0013500-Kawano1]. Conversely, ectopic expression of DKK3 resulted in decreased proliferation, inhibited colony formation and induced apoptosis of LNCaP, PC3 and DU145 cell lines [@pone.0013500-Lodygin1], [@pone.0013500-Kawano1]. In our patient samples, DKK3 expression decreased in prostate cancer and lymph node metastasis, but no difference was observed in hormone-refractory samples ([Fig. 5B](#pone-0013500-g005){ref-type="fig"}). As for TWIST1, DKK3 might be useful as a cancer marker, but could not predict tumor progression, nor explain recurrence after hormonal therapy. Interestingly, injection of an adenovirus vector carrying DKK3 showed a dramatic anti-tumor effect in a xenograft human PCa model, inhibiting tumor growth and lymph node metastasis and prolonging mice survival [@pone.0013500-Edamura1]. Such results encourage the development of therapies targeting DKK3 in advanced metastatic disease.

An important limitation of the present study and other transcript profiling studies is that, in most cases, the functional biological entity is the protein, not the measured mRNA. For all of our validated genes of interest (VAV3, TWIST1 and DKK3), it has previously been established that the level of the mRNA expression is representative for its protein level, in pulmonary fibrosis, gastric cancer and various cell lines [@pone.0013500-Lyons1], [@pone.0013500-Bridges1], [@pone.0013500-YanQi1], [@pone.0013500-Hu1], [@pone.0013500-SaebParsy1].

In conclusion, the present study shows that AR overexpression (in PC346Flu1) and mutation (in PC346Flu2) may allow for the maintenance of the AR activity under androgen ablation and antiandrogen treatment. In contrast, PCa cells may acquire complete independence from AR signaling by activating alternative survival pathways, as exemplified by PC346DCC. In PC346DCC, activation of VAV3 and TWIST1 oncogenes and down-regulation of DKK3 tumor suppressor constitutes a possible mechanism for bypassing the AR pathway. The fact that TWIST1 and DKK3 expression was deregulated in both hormone-refractory and hormone-naïve patient samples, suggests that these alterations occur earlier in PCa progression and do not act alone in inducing therapy-resistant growth. Indeed, both VAV3 and TWIST1 are known to interact with growth factor signaling, which could be the effector mechanism in stimulating cellular proliferation. Additionally, DKK3 down-regulation may promote survival through inhibition of apoptosis. These results grant further investigations on the use of VAV3, TWIST1 and DKK3 as prostate cancer markers and in the development of targeted therapies for advanced disease.
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